

Aytu Biopharma, Inc. (AYTU)

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001385818

Aytu Biopharma, Inc. AYTU; healthcare	
Grade	E A B C D E weakest fifth of 371 graded peers percentile 90.5; sampling error 2.5 points; lower is stronger
Rank	336 of 371
Profitability	C percentile 49.4
Solvency	E percentile 86.9
Growth and financing	D percentile 68.7
Reliability	0.83 AUC filers with \$12.5M to \$120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025
Peer failure rate	1.07% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	\$12.5M to \$120M assets total assets \$105.0M
Standard universe	inside revenue above \$1M and assets above \$10M
Warnings	none active; fortress balance sheet not computable: distress
Inputs computable	7 of 14
Graded from	filings received through Sep 22, 2026 17 days before the rescan; latest periodic filing 10-K received Sep 22, 2026
Last close	\$2.10 2026-10-05; market equity \$22.9M
Price used in grade	None




E, the bear

weakest fifth of its sector;
letters are fifths of the 371
graded peers

Share price, twelve months to the rescan


split-adjusted close; the letter is fixed at the rescan that set it



Rescans on file: D/E from Apr 21, 2024, B from Oct 21, 2024, E from Oct 21, 2025, E from Sep 26,

Letter at every rescan

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only



Business, in the company's words

opening of Item 1 of the 10-K received Sep 22, 2026

Aytu BioPharma, Inc. ("Aytu," the "Company," "we," "us," or "our") is a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients. We were originally incorporated as Rosewind Corporation on August 9, 2002, in the state of Colorado and re-incorporated as Aytu BioScience, Inc. in the state of Delaware on June 8, 2015. In March 2021, we changed our name to Aytu BioPharma, Inc. Our common stock trades on the Nasdaq

Capital Market LLC (the "Nasdaq") under the ticker symbol "AYTU.

The fourteen inputs

lower percentile is stronger; equal-weighted sleeves

Input	Percentile, 0 to 100	Value	Peer median	Percentile	Peers	Period end
Profitability, sleeve percentile 49.4						
Gross profitability		35.1%	32.2%	39.1	372	2026-06-30
Return on invested capital		not computable	9.3%			pretax income must exceed the validity floor and imply a 0%-100% tax rate
Accruals ratio		(15.3%)	(6.6%)	28.9	811	2026-06-30
Gross margin stability, five years		7.1 pts	2.8 pts	80.2	243	2026-06-30
Solvency, sleeve percentile 86.9						
Twelve-month failure probability		not computable	0.07%			liabilities and a nearby cover-page share count are required at 2026-06-30 latest aligned
Altman Z double-prime		not computable	(0.31)			inputs end 2023-06-30; latest annual assets end 2026-06-30
Net debt to EBITDA		not computable	1.82x			EBITDA must exceed \$100,000 latest aligned
Interest coverage		not computable	(4.51x)			inputs end 2020-06-30; latest annual assets end 2026-06-30
Current ratio		1.13x	2.96x	86.9	839	2026-06-30
Growth and financing, sleeve percentile 68.7						
Revenue growth, three-year compound		(18.8%)	10.0%	88.6	415	2026-06-30
Free cash flow growth, three-year compound		not computable	10.9%			four consecutive annual FCF observations are required; found 8
Reinvestment rate		not computable	37.1%			pretax income must exceed the validity floor and imply a 0%-100% tax rate
Asset growth, three years		(8.4%)	2.1%	66.3	704	2026-06-30
Net share issuance, one year		9.6%	2.5%	51.0	634	2026-09-15


Warnings

1 of 7 checks triggered; none of them enters the letter

Check	Measured
Fortress balance sheet	cash minus debt is 17,207,000 USD; Altman Z is not used

Among 371 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
331	Nuwellis, Inc. (NUWE)	89.2	E	dilution, short runway, fortress balance sheet
332	Aclaris Therapeutics, Inc. (ACRS)	89.5	E	short runway, fortress balance sheet
333	Brookdale Senior Living Inc. (BKD)	89.7	E	
334	Lifeward Ltd. (LFWD)	90.0	E	dilution, late filer
335	Canopy Growth Corp. (CGC)	90.3	E	dilution, fortress balance sheet
336	Aytu Biopharma, Inc. (AYTU) <	90.5	E	fortress balance sheet
337	Q32 Bio Inc. (QTTB)	90.8	E	
338	Editas Medicine, Inc. (EDIT)	91.1	E	fortress balance sheet
339	Dyadic International Inc. (DYAI)	91.4	E	short runway, distress
340	Century Therapeutics, Inc. (IPSC)	91.6	E	dilution, fortress balance sheet
341	Beyond Air, Inc. (XAIR)	91.9	E	dilution, short runway, distress

What the price implies

at the 2026-10-05 close; none enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	21.8%	8.0%	61
Distance from 52-week high	(29.3%)	(31.4%)	53
EBIT to enterprise value	(164.0%)	(1.5%)	4
Free cash flow yield	14.6%	(1.0%)	94
Book value to price	1.58	0.28	94
Sales to price	2.58	0.31	93
Composite equity issuance, five years	206.5%	20.3%	90

Diagnostics

not in the grade

Measure	Value
Piotroski F-score 4 of 9, period end 2026-06-30	
Return on assets above zero	fail
Operating cash flow above zero	pass
Return on assets improved	pass
Operating cash flow exceeds net income	pass
Long-term leverage fell	pass
Current ratio improved	fail
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	\$26.3M
Operating cash flow, four quarters	\$3.3M
Months of runway	not finite
Days since last periodic filing	17 (10-K received Sep 22, 2026)
Median daily dollar volume, 63 sessions	\$49,010

Sources

each row links to the filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	\$36.8M	2026-06-30	2026-09-22	10-K	0001437749-26-030908
2	assets	us-gaap:Assets	\$105.0M	2026-06-30	2026-09-22	10-K	0001437749-26-030908
3	operating income	us-gaap:OperatingIncomeLoss	-\$8.3M	2026-06-30	2026-09-22	10-K	0001437749-26-030908
4	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItems	\$114.2M	2026-06-30	2026-09-22	10-K	0001437749-26-030908
5	income tax	us-gaap:IncomeTaxExpenseBenefit	\$21,000	2026-06-30	2026-09-22	10-K	0001437749-26-030908
6	total debt	us-gaap:LongTermDebtAndCapitalLeaseObligations	\$9.1M	2026-06-30	2026-09-22	10-K	0001437749-26-030908
7	book equity	us-gaap:StockholdersEquity	\$35.3M	2026-06-30	2026-09-22	10-K	0001437749-26-030908
8	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	\$26.3M	2026-06-30	2026-09-22	10-K	0001437749-26-030908
9	total debt	us-gaap:LongTermDebtAndCapitalLeaseObligations	\$10.9M	2025-06-30	2026-09-22	10-K	0001437749-26-030908
10	book equity	us-gaap:StockholdersEquity	\$19.0M	2025-06-30	2026-09-22	10-K	0001437749-26-030908
11	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	\$31.0M	2025-06-30	2026-09-22	10-K	0001437749-26-030908
12	net income	us-gaap:NetIncomeLoss	-\$14.3M	2026-06-30	2026-09-22	10-K	0001437749-26-030908
13	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$3.3M	2026-06-30	2026-09-22	10-K	0001437749-26-030908
14	assets	us-gaap:Assets	\$124.2M	2025-06-30	2026-09-22	10-K	0001437749-26-030908
15	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$57.6M	2026-06-30	2026-09-22	10-K	0001437749-26-030908
16	gross profit	us-gaap:GrossProfit	\$45.8M	2025-06-30	2026-09-22	10-K	0001437749-26-030908
17	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$66.4M	2025-06-30	2026-09-22	10-K	0001437749-26-030908
18	gross profit	us-gaap:GrossProfit	\$49.1M	2024-06-30	2025-09-23	10-K	0001437749-25-029723
19	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$65.2M	2024-06-30	2025-09-23	10-K	0001437749-25-029723
20	gross profit	us-gaap:GrossProfit	\$66.6M	2023-06-30	2024-09-26	10-K	0001437749-24-030062
21	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$107.4M	2023-06-30	2024-09-26	10-K	0001437749-24-030062
22	gross profit	us-gaap:GrossProfit	\$52.3M	2022-06-30	2023-10-12	10-K	0001558370-23-016393
23	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$96.7M	2022-06-30	2023-10-12	10-K	0001558370-23-016393
24	current assets	us-gaap:AssetsCurrent	\$72.8M	2023-06-30	2023-10-12	10-K	0001558370-23-016393
25	current liabilities	us-gaap:LiabilitiesCurrent	\$69.0M	2023-06-30	2024-09-26	10-K	0001437749-24-030062
26	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-\$304.1M	2023-06-30	2024-09-26	10-K	0001437749-24-030062
27	operating income	us-gaap:OperatingIncomeLoss	-\$17.1M	2023-06-30	2024-09-26	10-K	0001437749-24-030062
28	book equity	us-gaap:StockholdersEquity	\$39.4M	2023-06-30	2025-09-23	10-K	0001437749-25-029723
29	assets	us-gaap:Assets	\$136.5M	2023-06-30	2024-09-26	10-K	0001437749-24-030062
30	liabilities	us-gaap:Liabilities	\$97.1M	2023-06-30	2023-10-12	10-K	0001558370-23-016393
31	depreciation amortization	us-gaap:Depreciation	\$100,000	2026-06-30	2026-09-22	10-K	0001437749-26-030908
32	operating income	us-gaap:OperatingIncomeLoss	-\$21.1M	2020-06-30	2021-09-28	10-K	0001558370-21-012825
33	interest expense	us-gaap:InterestExpense	\$2.6M	2020-06-30	2020-10-06	10-K	0001654954-20-010891
34	current assets	us-gaap:AssetsCurrent	\$61.8M	2026-06-30	2026-09-22	10-K	0001437749-26-030908
35	current liabilities	us-gaap:LiabilitiesCurrent	\$54.7M	2026-06-30	2026-09-22	10-K	0001437749-26-030908

36	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$29,000	2026-06-30	2026-09-22	10-K	0001437749-26-030908
37	current assets	us-gaap:AssetsCurrent	\$79.2M	2025-06-30	2026-09-22	10-K	0001437749-26-030908
38	current liabilities	us-gaap:LiabilitiesCurrent	\$63.1M	2025-06-30	2026-09-22	10-K	0001437749-26-030908
39	assets	us-gaap:Assets	\$118.1M	2024-06-30	2025-09-23	10-K	0001437749-25-029723
40	shares outstanding	dei:EntityCommonStockSharesOutstanding	10,866,708	2026-09-15	2026-09-22	10-K	0001437749-26-030908
41	shares outstanding	dei:EntityCommonStockSharesOutstanding	9,911,913	2025-09-15	2025-09-23	10-K	0001437749-25-029723